Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a Memorandum of Understanding (MoU) with the International Olympic Committee (IOC) to donate the companies’ COVID-19 vaccine to help vaccinate athletes, and their delegations, participating in the Olympic and Paralympic Games Tokyo 2020, which are scheduled to begin on July 23, 2021.
Under the MoU, the companies and the IOC will coordinate with National Olympic Committees (NOCs) around the world to understand and work to help address the local need for vaccine doses for national delegations’ participation in the Games. Delivery of initial doses to participating delegations is expected to begin at the end of May where possible with the aim to ensure participating delegations receive second doses ahead of arrivals in Tokyo. Under the MoU framework, NOCs and their local governments are expected to coordinate the administration of vaccinations to eligible Games participants. Doses provided under this MoU would be in addition to doses provided under supply agreements with governments worldwide. The donation of vaccine doses will not affect the supply of the national populations with COVID-19 doses under the supply agreements.
“This donation of the vaccine is another tool in our toolbox of measures to help make the Olympic and Paralympic Games Tokyo 2020 safe and secure for all participants and to show solidarity with our gracious Japanese hosts,” said IOC President Thomas Bach. “We are inviting the athletes and participating delegations of the upcoming Olympic and Paralympic Games to lead by example and accept the vaccine where and when possible. By taking the vaccine, they can send a powerful message that vaccination is not only about personal health, but also about solidarity and consideration of the wellbeing of others in their communities. We would like to thank Pfizer and BioNTech for this very generous donation to support the vaccination of athletes and Games participants ahead of the Olympic and Paralympic Games Tokyo 2020,” he added.
During a conversation between Albert Bourla, Chairman and Chief Executive Officer, Pfizer, and Suga Yoshihide, Prime Minister of Japan, which is the host country of Tokyo 2020, Mr. Bourla made an offer to donate the Pfizer-BioNTech COVID-19 vaccine for athletes and their delegations participating in Tokyo 2020. Following this conversation, the Japanese government had a meeting with the IOC and now the donation plan has been realized.
“With hundreds of millions of vaccines already administered, and hundreds of millions more to go, Pfizer is committed, together with BioNTech, to doing all we can to help end this pandemic and help return the world to a sense of normalcy,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “The return of the Olympic and Paralympic Games represents a monumental moment of world unity and peace after a grueling year of isolation and devastation. We are proud to play a role in providing vaccines to athletes and national Olympic delegations.”
“Providing vaccines to Games participants is one of the critical ways to help ensure the Games are as safe and successful as possible. With more than 430 million doses already delivered, our vaccine continues to help protect lives around the world and bring us back to our normal lives,” said Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “This year’s Olympic and Paralympic Games are an historic moment representing the global community and how we stand together. We are honored to be able to contribute vaccines to support the safety of the Olympic and Paralympic Games.”
It is the decision of sovereign States to offer immunization to athletes and their delegations in accordance with their local guidance before travelling to Japan for the Tokyo Games. The IOC and International Paralympic Committee (IPC) have made it clear that vaccination is not mandatory in order for athletes to participate in the Olympic and Paralympic Games, and that any vaccination program must be conducted in full respect of national vaccination priorities.
The Pfizer-BioNTech COVID-19 vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the European Union, and the holder of emergency use authorizations or equivalent in the United States (jointly with Pfizer), United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries.
The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564 (b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including Full EUA Prescribing Information available at www.cvdvaccine.com.
People In This Post
Companies In This Post
- Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors Read more
- Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) Read more
- BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey Read more
- Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution Read more
- GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey” Read more